Aura Biosciences (NASDAQ:AURA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Aura Biosciences (NASDAQ:AURA – Free Report) from a sell rating to a hold rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Other equities research analysts have also recently issued reports about the company. HC Wainwright decreased their price target on Aura Biosciences from $24.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aura Biosciences in a report on Monday, October 12th. Finally, Citigroup restated a “market outperform” rating on shares of Aura Biosciences in a research note on Tuesday, November 10th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $17.50.

Get Our Latest Stock Report on AURA

Aura Biosciences Stock Up 1.5%

Shares of AURA stock opened at $7.22 on Friday. Aura Biosciences has a 12-month low of $4.73 and a 12-month high of $9.53. The business’s fifty day simple moving average is $6.54 and its 200-day simple moving average is $6.78.

Aura Biosciences (NASDAQ:AURA – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.08. As a group, research analysts forecast that Aura Biosciences will post -1.48 earnings per share for the current year.

Institutional Investors Weigh In On Aura Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. Legal & General Group Plc acquired a new position in Aura Biosciences in the 2nd quarter worth approximately $29,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Aura Biosciences during the 3rd quarter worth approximately $33,000. Parallel Advisors LLC raised its position in Aura Biosciences by 130.4% during the 1st quarter. Parallel Advisors LLC now owns 5,665 shares of the company’s stock worth $38,000 after buying an additional 3,206 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new stake in Aura Biosciences during the 2nd quarter valued at approximately $54,000. Finally, ProShare Advisors LLC acquired a new stake in Aura Biosciences during the 3rd quarter valued at approximately $68,000. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences Company Profile

(Get Free Report)

Aura Biosciences is a clinical-stage biotechnology company developing treatments for cancer, with a focus on therapies designed to selectively destroy tumor cells while limiting damage to surrounding healthy tissue. The company is headquartered in the Boston area. Its lead candidate, belzupacap sarotalocan (formerly AU-011), is an investigational therapy being studied for choroidal melanoma, a cancer that develops in the eye. It uses a virus-like particle linked to a light-activated compound; after the compound binds to tumor cells, near-infrared light activates it to damage those cells.

Further Reading

Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.